Cargando…

Nuclear osteopontin-c is a prognostic breast cancer marker

BACKGROUND: Although Osteopontin has been known as a marker for cancer progression, the elevated production of this cytokine is not specific for cancer. We have identified the splice variant Osteopontin-c as being absent from healthy tissue but associated with about 75% of breast cancer cases. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zduniak, K, Ziolkowski, P, Ahlin, C, Agrawal, A, Agrawal, S, Blomqvist, C, Fjällskog, M-L, Weber, G F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333500/ https://www.ncbi.nlm.nih.gov/pubmed/25625274 http://dx.doi.org/10.1038/bjc.2014.664

Ejemplares similares

Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides
por: Aaltonen, K, et al.
Publicado: (2006)

Osteopontin is a marker for cancer aggressiveness and patient survival
por: Weber, G F, et al.
Publicado: (2010)

Osteopontin splice variants are differential predictors of breast cancer treatment responses
por: Zduniak, Krzysztof, et al.
Publicado: (2016)

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer
por: Ihnen, M, et al.
Publicado: (2010)

Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer
por: Boldrini, L, et al.
Publicado: (2005)

Wnt–β-catenin–Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer
por: Ravindranath, A, et al.
Publicado: (2011)

Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma
por: Sim, S H, et al.
Publicado: (2012)

Validation of UBE2C protein as a prognostic marker in node-positive breast cancer
por: Loussouarn, D, et al.
Publicado: (2009)

Expression of osteopontin coregulators in primary colorectal cancer and associated liver metastases
por: Mole, D J, et al.
Publicado: (2011)

Expression of Osteopontin in oesophageal squamous cell carcinoma
por: Kita, Y, et al.
Publicado: (2006)

Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response
por: Thoms, J W, et al.
Publicado: (2012)

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer
por: Ali, H R, et al.
Publicado: (2012)

Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels
por: Rittling, S R, et al.
Publicado: (2014)

miR-30e* is an independent subtype-specific prognostic marker in breast cancer
por: D'Aiuto, F, et al.
Publicado: (2015)

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
por: Dawson, S-J, et al.
Publicado: (2010)

Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer
por: Wallin, U, et al.
Publicado: (2011)

Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse
por: Kahlert, C, et al.
Publicado: (2009)

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers
por: Sung, Hyuna, et al.
Publicado: (2016)

Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer
por: Smith, R A, et al.
Publicado: (2011)

Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer
por: Leitch, E F, et al.
Publicado: (2007)

Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma
por: Engels, C C, et al.
Publicado: (2014)

Epstein-Barr virus as a marker of biological aggressiveness in breast cancer
por: Mazouni, C, et al.
Publicado: (2011)

Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis
por: Mohammed, R A A, et al.
Publicado: (2007)

Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study
por: Wager, M, et al.
Publicado: (2008)

Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer
por: Zhu, C-Q, et al.
Publicado: (2006)

The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer
por: Talieri, M, et al.
Publicado: (2009)

Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer
por: Voss, M A, et al.
Publicado: (2011)

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas
por: Loussouarn, D, et al.
Publicado: (2008)

Nuclear CSPP1 expression defined subtypes of basal-like breast cancer
por: Sternemalm, J, et al.
Publicado: (2014)

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
por: Zagouri, F, et al.
Publicado: (2013)

ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels
por: Rondeau, S, et al.
Publicado: (2015)

Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?
por: Karayan-Tapon, L, et al.
Publicado: (2008)

Prognostic significance of epithelial–mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray
por: Nitta, T, et al.
Publicado: (2014)

Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer
por: Hector, S, et al.
Publicado: (2012)

Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC
por: Strell, Carina, et al.
Publicado: (2017)

A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms
por: Khan, M S, et al.
Publicado: (2013)

Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer
por: Ali, A M G, et al.
Publicado: (2011)

Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype
por: Grelier, G, et al.
Publicado: (2009)

Proteomic profiling of the hypothalamus in a mouse model of cancer-induced anorexia-cachexia
por: Ihnatko, R, et al.
Publicado: (2013)

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance
por: Palmieri, C, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_r1drgp4v8k2aorr1ij9kdcp58c